Host: Matt Birnholz, MD

Guest: Edward S. Kim, MD, FACP

Lung cancer is the leading cause of cancer-associated mortality, with almost 225,000 new cases and over 158,000 deaths estimated in 2016 in the United States alone. Non-small cell lung cancer (NSCLC) represents approximately 85% of those cases. Join us as Dr. Birnholz and Dr. Kim review the data presented at the 2016 annual ESMO conference and discuss the continued rise of anti-PD-1 therapy in the treatment of NSCLC. Since the recording of this interview, pembrolizumab was approved by the FDA on October 24, 2016 for use in Non-small Cell Lung Cancer.